496 related articles for article (PubMed ID: 30753579)
1. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.
Schiff D; Van den Bent M; Vogelbaum MA; Wick W; Miller CR; Taphoorn M; Pope W; Brown PD; Platten M; Jalali R; Armstrong T; Wen PY
Neuro Oncol; 2019 Jul; 21(7):837-853. PubMed ID: 30753579
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Miller JJ; Gonzalez Castro LN; McBrayer S; Weller M; Cloughesy T; Portnow J; Andronesi O; Barnholtz-Sloan JS; Baumert BG; Berger MS; Bi WL; Bindra R; Cahill DP; Chang SM; Costello JF; Horbinski C; Huang RY; Jenkins RB; Ligon KL; Mellinghoff IK; Nabors LB; Platten M; Reardon DA; Shi DD; Schiff D; Wick W; Yan H; von Deimling A; van den Bent M; Kaelin WG; Wen PY
Neuro Oncol; 2023 Jan; 25(1):4-25. PubMed ID: 36239925
[TBL] [Abstract][Full Text] [Related]
3. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
[TBL] [Abstract][Full Text] [Related]
4. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
5. Diffuse Infiltrating Oligodendroglioma and Astrocytoma.
van den Bent MJ; Smits M; Kros JM; Chang SM
J Clin Oncol; 2017 Jul; 35(21):2394-2401. PubMed ID: 28640702
[TBL] [Abstract][Full Text] [Related]
6. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Miller JJ; Shih HA; Andronesi OC; Cahill DP
Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
[TBL] [Abstract][Full Text] [Related]
8. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
[TBL] [Abstract][Full Text] [Related]
9. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y
Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
[TBL] [Abstract][Full Text] [Related]
11. MRI and CT Identify Isocitrate Dehydrogenase
Patel SH; Batchala PP; Mrachek EKS; Lopes MS; Schiff D; Fadul CE; Patrie JT; Jain R; Druzgal TJ; Williams ES
Radiology; 2020 Jan; 294(1):160-167. PubMed ID: 31714193
[TBL] [Abstract][Full Text] [Related]
12. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.
Patel SH; Bansal AG; Young EB; Batchala PP; Patrie JT; Lopes MB; Jain R; Fadul CE; Schiff D
AJNR Am J Neuroradiol; 2019 Jul; 40(7):1149-1155. PubMed ID: 31248860
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A
Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427
[TBL] [Abstract][Full Text] [Related]
14. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
15. What's New in Grade II and Grade III Gliomas?
Miller JJ; Wick W
Semin Neurol; 2018 Feb; 38(1):41-49. PubMed ID: 29548051
[TBL] [Abstract][Full Text] [Related]
16. Biological tumour volumes of gliomas in early and standard 20-40 min
Unterrainer M; Winkelmann I; Suchorska B; Giese A; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1242-1249. PubMed ID: 29487977
[TBL] [Abstract][Full Text] [Related]
17. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
18. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.
Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D
J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272
[TBL] [Abstract][Full Text] [Related]
19. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
20. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]